Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with TIL and IL-2 in Metastatic Melanoma
NCT02500576Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2015
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02500576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500576.